ITeos Therapeutics Inc logo

ITOS

ITeos Therapeutics Inc

$23.25

Earnings Summary

Revenue
$152.52Mn
Net Profits
$69.58Mn
Net Profit Margins
45.62%
PE Ratio
2.97

Highlights

Revenue:

ITeos Therapeutics Inc’s revenue jumped +Inf% since last year same period to $152.52Mn in the Q1 2022. On a quarterly growth basis, ITeos Therapeutics Inc has generated 246.76% jump in its revenue since last 3-months.

Net Profits:

ITeos Therapeutics Inc’s net profit jumped 614.13% since last year same period to $69.58Mn in the Q1 2022. On a quarterly growth basis, ITeos Therapeutics Inc has generated 336.4% jump in its net profits since last 3-months.

Net Profit Margins:

ITeos Therapeutics Inc’s net profit margin jumped NaN% since last year same period to 45.62% in the Q1 2022. On a quarterly growth basis, ITeos Therapeutics Inc has generated 61.08% jump in its net profit margins since last 3-months.

PE Ratio:

ITeos Therapeutics Inc’s price-to-earnings ratio after this Q1 2022 earnings stands at 2.97.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the ITeos Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
1.2
EPS Estimate Current Year
1.2

Highlights

EPS Estimate Current Quarter:

ITeos Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at 1.2 - a 50% jump from last quarter’s estimates.

EPS Estimate Current Year:

ITeos Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at 1.2.

Key Ratios

Key ratios of the ITeos Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
1.82
Return on Assets (ROA)
0.46
Return on Equity (ROE)
0.71
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

ITeos Therapeutics Inc’s earning per share (EPS) jumped 566.67% since last year same period to 1.82 in the Q1 2022. This indicates that the ITeos Therapeutics Inc has generated 566.67% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ITeos Therapeutics Inc’s return on assets (ROA) stands at 0.46.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ITeos Therapeutics Inc’s return on equity (ROE) stands at 0.71.

Dividend Per Share (DPS):

ITeos Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
0.8
1.82
127.5%

Company Information

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of cancer immunology and immunosuppressive pathways to design novel product candidates with the potential to fully restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1/2a clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity in the dose escalation portion of the trial. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.

Organisation
ITeos Therapeutics Inc
Employees
62
Industry
Health Technology